Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

How durable are the mRNA Covid vaccines? Does the protection last as long as other vaccines? Experts the vaccines are ...

Moderna's new £150million vaccine factory in Oxfordshire is nearly finished and about to start production. The biotechnology company has invested "millions" in the plant which will create between 150 ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

If the influenza virus infecting cattle workers starts a pandemic, help in the form of a vaccine is months away ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Moderna, a biotech giant that gained prominence during the COVID-19 pandemic, has revolutionized the biotechnology domain.

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar with the ...